San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.
Learning ability, criminality, drug response may be discerned, scientists say.
Learning ability, criminality, drug response may be discerned, scientists say.
NEW YORK, Jan. 7, 2015 /PRNewswire/ — Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today announced that David P. Luci, President & Chief Executive Officer, will be presenting at the Biotech Showcase™ 2015 Conference being held in San Francisco, California.
Details of Dipexium’s presentation are as follows:
Biotech Showcase™ 2015 Conference
Tuesday, January 13, 2015
4:30 pm Pacific Time
Room D Powell Parc 55 Wyndham San Francisco Union Square Hotel
Co-produced by Demy-Colton Life Science Advisors and EBD Group, Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry’s largest annual healthcare investor conferences. Now in its seventh year, Biotech Showcase™ is expected to attract upwards of 1,500 attendees.
About Dipexium Pharmaceuticals, Inc.
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) is a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide. Initially, Locilex® is targeted for the treatment of mild infections of diabetic foot ulcers. Based on a compilation of available clinical and microbiology data, Locilex® is also considered a promising product candidate to treat other mild and moderate skin and skin structure infections, including infected decubitus ulcers, infected burns, infected surgical wounds and nasal colonization of methicillin-resistant staphylococcus aureus (MRSA).
Cautionary Note on Forward-Looking Statements
This press release and any statements of representatives and partners of Dipexium Pharmaceuticals, Inc. (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission and those that relate to the Company’s ability to leverage the expertise of employees and partners to assist the Company in the execution of its strategy. Actual results (including, without limitation, the timing for and results of the clinical trials and proposed NDA submission for Locilex®) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
David P. Luci
President & Chief Executive Officer
Dipexium Pharmaceuticals, Inc.
Vice President, Finance & Corporate Development
Dipexium Pharmaceuticals, Inc.
© 2015 Dipexium Pharmaceuticals, Inc. All rights reserved.
SOURCE Dipexium Pharmaceuticals, Inc.
Reset Therapeutics Announces Expansion of its Drug Discovery Platform via an Agreement with 23andMe Incorporating the Genetics of Circadian Rhythms
Collaboration Aims to Generate New Therapeutic Approaches for Chronic Diseases
SAN FRANCISCO, Jan. 7, 2015 /PRNewswire/ — Reset Therapeutics, a company dedicated to the discovery and development of novel drugs that restore the body’s natural 24-hour physiological rhythms, announced today a research agreement with 23andMe. The goal of the research collaboration with 23andMe is to study circadian clock genes and ultimately improve therapeutic development for diseases related to molecular clocks.
Research into the composition, function, and effects of molecular clocks has demonstrated that disruption of normal circadian rhythms is associated with diseases of the central nervous system, immune system dysfunction, cardiovascular and metabolic disorders and cancer. Data suggest that resetting the circadian system resynchronizes biological processes with environmental demands, potentially resulting in therapies that target causes of disease, rather than just treating symptoms.
Through this collaboration, the Reset team will be able to conduct research from more than 650,000 23andMe customers who have consented for their de-identified aggregated data to be a part of research. Specifically, Reset finds the clock genes most consistently associated with chronotype, sleep, insulin resistance, stress response and related pathophysiology to identify novel circadian drug targets and to stratify patients and identify secondary indications for its existing therapeutic development programs.
“Reset is dedicated to creating precision approaches to treating orphan and larger metabolic diseases by restoring normal clock function to patients whose rhythms have become dysregulated,” said Ross Bersot, CFA, president and CEO, Reset Therapeutics. “Working with 23andMe, we will amplify our R&D capabilities by incorporating a large scale human genetics element in our research platform in a way that wasn’t possible. With this collaboration we will be able to more efficiently and effectively drive our clinical programs. This demonstrates the power of bringing together disease insights generated by researchers in academia, state-of-the art drug discovery and chemistry expertise built by Reset, and patient-empowered genomic models of research championed by 23andMe.”
“Deeper insight into the genetics of circadian rhythms may lead to better treatments for a variety of diseases and disorders,” said 23andMe Director of Business Development Emily Drabant-Conley, Ph.D. “It is an area that has been of interest to our research team for some time, and this collaboration with Reset provides the drug discovery and development resources needed to actually translate our insights into better therapies for patients.”
Terms of the agreement are not disclosed.
About Reset Therapeutics
Reset is a discovery-stage biopharma company developing first-in-class approaches to treating orphan diseases by restoring the body’s natural 24-hour, or circadian, rhythms. Founded in 2008, Reset has elucidated the connections between circadian clock function and disease and discovered new treatments that modulate these connections.
23andMe, Inc. is the leading personal genetics company dedicated to helping people access, understand and benefit from the human genome. Founded in 2006, the vision for 23andMe is to personalize healthcare by making and supporting meaningful discoveries through genetic research. More information is available at 23andMe.com.
SOURCE Reset Therapeutics
San Diego company readies final stage of testing an experimental fat-sculpting drug.
San Diego company readies final stage of testing an experimental fat-sculpting drug.
CARLSBAD, CA–(Marketwired – January 07, 2015) – International Stem Cell Corporation ( OTCQB : ISCO ), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today that the Company’s Chief Financial Officer, Mr. Jay Novak, Chief Scientific Officer, Ruslan Semechkin Ph.D., and Executive Vice President, Simon Craw Ph.D. will attend the Biotech ShowcaseT 2015 Conference being held in San Francisco, CA from January 12 through 14, 2015. Dr. Craw will present a corporate overview.
Paul Bunn, Jr., M.D. and Ralph de Vere White, M.D. accept HealthTell Scientific Advisory roles to Support Accurate and Affordable Cancer Detection Using a Single Drop of Blood
SAN RAMON, Calif., Jan. 7, 2015 /PRNewswire/ — HealthTell™, an early stage Life Sciences company, today announced two distinguished advisers, Paul Bunn, Jr., M.D. and Ralph de Vere White, M.D., have joined HealthTell’s team as Scientific Advisors. As leaders in Oncology, Dr. Bunn is considered a foremost expert and adviser in Lung Cancer detection and monitoring, while Dr. de Vere White brings 44 years of experience in patient care and research in urology-based diseases, with emphasis on prostate and bladder cancer.
HealthTell’s Scientific Advisors will leverage their specific disease expertise as the company builds its Immunosignature™ Technology to measure a person’s real-time response to over 30 identified diseases. HealthTell’s Scientific Advisors will conduct research across disease states and collaborate with HealthTell, to validate various immune signatures.
“We are building a world class advisory team with expertise throughout various disease categories, including oncology, infectious disease, autoimmune, neurology, and metabolic disorders,” said Bill Colston, Ph.D., CEO of HealthTell. “Drs. Bunn and de Vere White offer leadership in lung, prostate and bladder cancer diagnosis, treatment, and monitoring. We are honored that both highly respected leaders in the oncology space will be contributing their professionalism to improve patient outcomes, decrease unnecessary diagnostic procedures, and improve the patient experience.”
Having earned his M.D. from Cornell University, Dr. Bunn joined the University of Colorado (CU) Health Sciences Center in 1984 and became a Professor of Medicine in Medical Oncology at the University. He is currently a distinguished professor at CU. Dr. Bunn’s research interests focus on novel therapies for lung cancer. He has published more than 300 articles in peer-reviewed journals, 122 reviews and 90 book chapters on lung cancer. Dr. Bunn’s studies have identified biomarkers of prognosis and therapy selection, and set standards for the treatment of lung cancer.
“Lung Cancer is notoriously difficult to catch, leading to a low 16 percent survival rate. While low dose CT scans are used for screening some patients, it results in very high rates of falsely identified cancer, which often leads to unnecessary, expensive and dangerous follow-up,” said Dr. Bunn. “HealthTell’s unique platform to detect changes in the immuno-response to cancer, rather than the cancer itself, may provide the breakthrough we desperately need to detect lung cancer in the early stage, which will reduce costs in diagnosis and hopefully identify patients in the early stages of cancer, when treatment is most effective.”
Dr. de Vere White joins HealthTell as Assistant Dean for Cancer Programs at the UC Davis School of Medicine. He is Director of the UC Davis Comprehensive Cancer Center and a distinguished professor in the Department of Urology. He received his medical degree from Dublin University in Dublin, Ireland, and completed his internship and residencies in surgery and urology at St. Vincent’s Hospital in Dublin and at Duke University Medical Center. The author of more than 300 peer-reviewed scientific articles and book chapters, Dr. de Vere White is highly respected in the urology space.
“A cancer diagnostic that requires only a drop of blood will have a major impact on the way we monitor bladder cancer in the future,” said Dr. de Vere White. “Today, bladder cancer patients experience a 30 to 70 percent recurrence rate, which requires quarterly follow-up that is both invasive and uncomfortable for patients. The ability to monitor a patient’s health, particularly those who reside in rural America would truly transform follow-up for patients.”
HealthTell is thrilled to embrace their first two advisors, Drs. Bunn and de Vere White and will continue to build a competent Scientific Advisor Team with physicians and researchers from around the world spanning multiple disease states.
HealthTell is an early stage Life Sciences company that utilizes an Immunosignature™ Technology for accurate and timely detection and monitoring of more than 30 progressive diseases. Based on robust, proprietary technology, the company is developing the first and only diagnostic platform capable of assessing an individual’s immune system response to specific diseases. This disruptive technology enables physicians to detect the presence or absence of a disease in its earliest stage, improving patient outcomes and reducing healthcare expenditures. Applicable to a broad range of therapeutic areas, HealthTell is empowering physicians and patients to proactively manage one’s health and make more informed decisions. For more information, please visit: http://www.healthtell.com/
Arcturus Therapeutics to Present Messenger RNA Pipeline at the 33rd Annual J.P. Morgan Healthcare Conference and the 7th Annual Biotech Showcase
- Announces new messenger RNA therapeutics pipeline using LUNAR(TM) delivery technology and UNA-messenger RNA (UmRNA)- Messenger RNA pipeline programs include thrombopoietin (LUNAR-TPO) for the management of thrombocytopenia, ornithine transcarbamylase (LUNAR-OTC) for the treatment of ornithine transcarbamylase deficiency, hepcidin (LUNAR-HPN) for the treatment of iron disorders, and cystic fibrosis transmembrane conductance regulator (LUNAR-CF) for the treatment of cystic fibrosis
SAN DIEGO, Jan. 7, 2015 /PRNewswire/ — Arcturus Therapeutics Inc., developing the ‘next wave’ of RNA medicines, today announced that Joseph Payne, President and Chief Executive Officer, is scheduled to present a corporate overview, including the company’s new messenger RNA (mRNA) therapeutics pipeline, at two upcoming healthcare conferences:
Event: 7th Annual Biotech Showcase
When: January 13, 2015 at 8:15 AM PST
Where: A-Hearst (4th Floor), Parc 55 Wyndham Union Square, San Francisco, CA
Event: 33rd Annual J.P. Morgan Healthcare Conference
When: January 14, 2015 at 5:00 PM PST
Where: Elizabethan D (private company track), Westin St. Francis Hotel, San Francisco, CA
“Since the inception of Arcturus we have been building our mRNA capabilities. We have proven LUNAR™ to be a potent and well tolerated delivery system for mRNAs and have demonstrated biological proof of concept for the up-regulation of erythropoietin and alpha-1 antitrypsin, using modified messenger RNA in non-human primates,” said Joseph Payne, President and Chief Executive Officer. “Further, we have built in-house mRNA synthesis capabilities at our new facility and have shown that the incorporation of UNA into mRNA (UmRNA) can increase stability and therefore longevity to mRNA medicines. Both LUNAR™ and UNA technologies are wholly-owned by Arcturus providing the company with a unique position from which to capitalize on its leading RNA delivery and chemistry technologies for the burgeoning field of messenger RNA therapeutics.”
Messenger RNA provides a novel way for the body to naturally express therapeutic molecules to treat diseases that were previously inaccessible. The newly announced Arcturus pipeline of mRNA programs include:
LUNAR-TPO: LUNAR-formulated thrombopoietin (TPO) mRNA for the treatment of thrombocytopenia, which often occurs as a result of a separate disorder, such as HCV, leukemia, an immune system problem, or as a medication side effect in the management of patients with cancer. TPO is a hormone produced by the liver and kidney, and is the most potent cytokine that regulates platelet production. The recovery of platelets after bone marrow transplantation or chemotherapy often occurs later than the recovery of other hematopoietic lineages and thus patients may require platelet transfusion to prevent hemorrhage. Even though platelet transfusion reduces the risk of hemorrhage, about 30% of transfusions result in complications including transmission of viral disease, febrile reactions, alloimmunization and sepsis. LUNAR-TPO is an example of the Arcturus approach to developing mRNA therapeutics for secreted proteins.
LUNAR-OTC: LUNAR-formulated ornithine transcarbamylase (OTC) mRNA for the treatment of ornithine transcarbamylase deficiency, the most common inherited urea cycle disorder in humans. OTC is a liver enzyme responsible for detoxification of ammonia and, if a person is deficient in OTC, ammonia levels will build up in the blood resulting in neurological problems and other toxicities. One in 70,000 adults has an ornithine transcarbamylase deficiency although reports suggest late-onset cases may go undetected such that overall incidence may be in the range of 1:20,000. Clinical onset is often rapid and devastating in a patient who is genetically affected; however, in older individuals, the initial onset can occur at age 40-50 years or older. Diagnosis includes the measurement of ammonia levels in the serum, which provides a convenient biomarker for preclinical and clinical assessment of LUNAR-OTC. The only curative approach is liver transplantation. LUNAR-OTC is an example of the Arcturus approach to developing mRNA therapeutics for intracellular proteins.
LUNAR-HPN: LUNAR-formulated hepcidin mRNA for the treatment of iron disorders. Hepcidin is a hormone synthesized and secreted by the liver that serves as a key regulator of iron levels in the circulation. Iron balance must be carefully regulated to provide iron as needed while avoiding toxicity associated with excess. Excessive iron absorption and tissue iron overload is one of the main features of Beta-thalassemia. Because the main cause of increased iron absorption in Beta-thalassemia is the low expression of hepcidin levels, a novel treatment strategy overexpressing hepcidin to limit iron overload has significant commercial potential. LUNAR-HPN is an example of the Arcturus approach to developing mRNA therapeutics for the liver.
LUNAR-CF: LUNAR-formulated cystic fibrosis transmembrane conductance regulator (CFTR) mRNA for the treatment of cystic fibrosis (CF), the most frequent lethal genetic disease in the Caucasian population. One in 2,500 newborns in the Caucasian population are affected by CF. CFTR is the main chloride channel in secretory epithelia and also acts as a regulator of sodium transport. This imbalance of active ion transport favors the net removal of salt and water from airway surfaces causing dehydration of the airway surface liquid, thereby impeding mucociliary clearance and creating a favorable microenvironment for bacterial infections. LUNAR-CF is an example of the Arcturus approach to developing mRNA therapeutics for the lung.
About Arcturus Therapeutics, Inc.
Founded in 2013 and based in San Diego, Arcturus Therapeutics is developing the ‘next wave’ of RNA medicines. Arcturus has invented a novel, potent and safe RNA Therapeutics platform called LUNAR™, a proprietary lipid-enabled delivery system for RNA medicines including BOTH small interfering RNA (siRNA) and messenger RNA (mRNA) therapeutics. The company’s UNA Oligomer™ chemistry technology and patent portfolio (34 patents, USPTO granted) enables the targeting of any gene in the human genome. Building a robust pipeline, Arcturus has focused internal efforts on RNA medicines for the treatment of rare diseases and, for larger indications, will be partnering with select companies that bring disease expertise. For more information, visit www.ArcturusRx.com.
SOURCE Arcturus Therapeutics, Inc.
Last month Juno Therapeutics closed a $250 million IPO, bringing the total raised since it was founded in Seattle in 2013 to close to $600 million. The money is earmarked to support more than ten…
[[Click headline to continue reading.]]